First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma
| Autor: | Melichar, B. *, Koralewski, P., Ravaud, A., Pluzanska, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Delva, R., Sevin, E., Négrier, S., McKendrick, J., Santoro, A., Pisa, P., Escudier, B. |
|---|---|
| Zdroj: | In Annals of Oncology August 2008 19(8):1470-1476 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|